GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors

Completed

• Conditions: Lung Tumor

• Registration Number: NCT03645915
• Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Brief Summary

Lung neuroendocrine tumor (LNT) represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker.

GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT.

The team have assessed the GLUT1 immunohistochemical staining in 36 LNT and to assess its diagnostic value.

Detailed Description

The (LNT) Lung neuroendocrine tumor represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker.

GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT.

Study Timeline

• Study Start: 2014-01-01
• Primary Completion: 2016-11-13
• Study Completion: 2016-11-13
• Status Verified: 2018-08
• Study First Submitted: 2018-08-22
• Study First Submitted QC: 2018-08-23
• Last Update Submitted: 2018-08-23
• Study First Posted: 2018-08-24
• Last Update Posted: 2018-08-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Patients with neuroendocrine tumors

Exclusion Criteria

• Patients without neuroendocrine tumors

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assess the GLUT1	5years	The objective of this study is to assess the GLUT1 staining in cohort of 36 cases of neuroendocrine tumors by immunohistochemistry and to assess its diagnostic interest.